相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
4°C, sealed storage, away from moisture
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- 规格:
10 mM * 1 mL/2 mg/5 mg/10 mg/50 mg
| 规格: | 10 mM * 1 mL | 产品价格: | ¥1475.0 |
|---|---|---|---|
| 规格: | 2 mg | 产品价格: | ¥800.0 |
| 规格: | 5 mg | 产品价格: | ¥1200.0 |
| 规格: | 10 mg | 产品价格: | ¥2046.0 |
| 规格: | 50 mg | 产品价格: | ¥5115.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
SU14813 maleate
CAS No. : 849643-15-8
MCE 国际站:SU14813 maleate
产品活性:SU14813 maleate是多靶点受体酪氨酸激酶抑制剂,抑制 VEGFR2,VEGFR1,PDGFRβ and KIT 的 IC50 值分别为50,2,4,15 nM。
研究领域:Protein Tyrosine Kinase/RTK
In Vitro: SU14813 inhibits ligand-dependent and ligand-independent proliferation, migration, and survival of endothelial cells and/or tumor cells expressing these targets. SU14813 inhibits cellular ligand-dependent phosphorylation of VEGFR-2 (transfected NIH 3T3 cells), PDGFR-β (transfected NIH 3T3 cells), KIT (Mo7e cells), and FLT3-internal tandem duplication (FLT3-ITD; MV4;11 cells) as well as FMS/CSF1R (transfected NIH 3T3 cells). SU14813 inhibits VEGFR-2, PDGFR-β, and KIT phosphorylation in porcine aorta endothelial cells overexpressing these targets, with cellular IC50 values of 5.2, 9.9, and 11.2 nM, respectively. SU14813 inhibits the growth of U-118MG with an IC50 of 50 to 100 nM.
In Vivo: SU14813 inhibits VEGFR-2, PDGFR-β, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent fashion. The plasma concentration required for in vivo target inhibition is estimated to be 100 to 200 ng/mL. Used as monotherapy, SU14813 exhibits broad and potent antitumor activity resulting in regression, growth arrest, or substantially reduced growth of various established xenografts derived from human or rat tumor cell lines. Treatment in combination with docetaxel significantly enhances both the inhibition of primary tumor growth and the survival of the tumor-bearing mice compared with administration of either agent alone.
相关产品:Bioactive Compound Library Plus | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | Anti-Cancer Compound Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Cytokine Inhibitors Library | Sorafenib | Lenvatinib | Pexidartinib | Sunitinib | Regorafenib | Nintedanib | Bevacizumab | Imatinib | Semaxinib | Cabozantinib | Ponatinib | Axitinib | Midostaurin | Chloramphenicol | Pazopanib | PD173074 | Crenolanib | 5Z-7-Oxozeaenol | Linifanib | Tanshinone IIA | Vandetanib | Foretinib | SU 5402 | Avapritinib | Fruquintinib | SPHINX31 | Masitinib
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验DNA纳米复合物的实时自组装监控—量子点-荧光共振能量转移(QD-FRET)和微流体的结合使用
0:05 DNA纳米复合物的实时自组装监控—量子点-荧光共振能量转移(QD-FRET)和微流体的结合使用5 0:21 内容订阅21 0:54 内容简介54 1:23 DNA生物素化、标记Cy5-阳离子聚合物83 5:51 制备量子点标记的DNA和Cy5-聚合物351 7:15 标准化光刻法制备SU-8光刻胶435 10:07 利用SU-8光刻胶铸造PDMS复制模型以及焊接至覆盖玻璃607 12:16 在微流体装置内监测DNA纳米复合物的形成736 13:30 由QD
有效性,为胶质瘤干细胞的实验研究和示踪,提供一种有效的病毒转染方法,为胶质瘤干细胞的研究提供基础。 1 材料与方法 1.1 实验材料和仪器 人脑胶质瘤干细胞、红色荧光蛋白基因的慢病毒(RFP-Lentivirus);CD133,Nestin 兔抗人,FITC、Cy3 免疫荧光试剂盒;DMEM/F-12,N2 添加剂,BFGF,EGF 因子;荧光显微镜,倒置显微镜;CO2 培养箱。 1.2 方法 (1)脑胶质瘤干细胞的培养与传代,鉴定 将人脑胶质瘤干细胞SU2 反复吹
反应,且具有很好的剂量依赖性,这使得比较候选化合物(药物)与 Bridion 的诱发过敏风险比较在动物模型上成为了可能。奥美克松钠的相关数据这里就不透露了,好戏才刚刚开始! 另一个新药血管生成抑肽 FpAT 是由北京市肿瘤防治研究所生化与分子生物学实验室在胃癌患者血清中发现的、由 15 个氨基酸组成的人内源性多肽,其申报适应症为抗肿瘤。该肽可特异进入血管内皮细胞,通过抑制内皮细胞的增殖、迁移及促凋亡等抑制血管的生成,进而发挥抗肿瘤作用,其分子机制可能与抑制鞘氨醇激酶活性有关。FpAT 属于特殊审评品种
技术资料暂无技术资料 索取技术资料














